Switching biologicals: Switching TNFα antagonists in psoriasis treatment

Dermatology

Volumn 216, Issue 4, 2008, Pages 281-282

  Schmitt Egenolf, Marcus ^a  

^a UMEÅ UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ETANERCEPT; IMMUNOGLOBULIN G; INFLIXIMAB;

COMORBIDITY; DRUG EFFICACY; EDITORIAL; GROUPS BY AGE; HUMAN; IMMUNOGENICITY; PHENOTYPE; PRIORITY JOURNAL; PSORIASIS; RHEUMATOLOGY; SEX DIFFERENCE;

BIOLOGICAL PRODUCTS; HUMANS; PSORIASIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 43049100778     PISSN: 10188665     EISSN: None     Source Type: Journal    
DOI: 10.1159/000113939     Document Type: Editorial

References (5)

1. Hyrich KL, Lunt M, Watson KD, Symmons DP, Silman AJ: Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum 2007;56:13-20.
2. Gomez-Reino JJ, Carmona L: Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period. Arthritis Res Ther 2006;8:R29.
3. Pitarch G, Sánchez-Carazo JL, Mahiques L, Oliver V: Efficacy of etanercept in psoriatic patients previously treated with infliximab. Dermatology 2008;216:312-316.
4. Papoutsaki M, Chimenti MS, Costanzo A, Talamonti M, Zangrilli A, Giunta A, Bianchi L, Chimenti S: Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics. J Am Acad Dermatol 2007;57:269-275.
5. Schmitt-Egenolf M: PsoReg - the Swedish registry for systemic psoriasis treatment: the registry's design and objectives. Dermatology 2007;214:112-117.